Why the study?
Systemic inflammation in takotsubo syndrome has been an underrated phenomenon in clinical practice despite rapidly accumulating experimental and clinical data.
This review highlights the pathogenetic, prognostic, and therapeutic implications of systemic inflammation in Takotsubo syndrome.
Systemic inflammation in Takotsubo warrants attention; leaves open prognostic and therapeutic roles pending prospective trials.
Over recent decades, systemic inflammation as quantified with inflammation markers or indices has been extensively investigated in the setting of various cardiovascular conditions including heart failure (HF), acute coronary syndromes (ACS). In contrast, systemic inflammation in patients with takotsubo syndrome (TTS) has been an underrated phenomenon in clinical practice. On the other hand, experimental and clinical data have been rapidly accumulating in the recent years regarding pathogenetic, prognostic as well as therapeutic implications of systemic inflammation in TTS. Accordingly, the present article aims to provide a general perspective on mechanistic and clinical aspects of systemic inflammation in the setting of TTS.
No takes yet. Share an insight, caveat, or question.
Yalta et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: